Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商建南德克公司filedCritical美商建南德克公司
Publication of TW202402328ApublicationCriticalpatent/TW202402328A/zh
Application grantedgrantedCritical
Publication of TWI848832BpublicationCriticalpatent/TWI848832B/zh
期刊 IAN E KROP ET AL Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial Lancet Oncol 18,6 20170516 1-12